2026 Volume: 02 Issue: 01 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-13

IMPACT OF UPDATED COVID-19 METHODOLOGICAL GUIDELINES ON CASE DETECTION AND MANAGEMENT IN INDIA: A REVIEW FOR UNDERGRADUATE MEDICAL TRAINING

***Riya Patil, Rutuja Sonar, & Roshan Shinde**

Abdimomunova B.T. Professor of Infectious Diseases.

Article Received: 13 December 2025
Article Revised: 1 January 2026
Published on: 20 January 2026

***Corresponding Author: Riya Patil**
Abdimomunova B.T. Professor of Infectious Diseases.

DOI: https://doi-doi.org/101555/ijrpa.3294

ABSTRACT

Background: The COVID-19 pandemic resulted in repeated revisions to Indian and global guidelines for surveillance, case definition, testing strategy, and clinical management. This, in turn, has great implications on the rapid identification of cases and the uniformity of management provided at different levels of care. **Objective:** To review how updated methodological guidelines for COVID-19 in India have impacted case detection and clinical management and to outline key learning points for undergraduate medical training. **Methods:** This narrative review used national documents from the Indian Council of Medical Research (ICMR) and Ministry of Health and Family Welfare (MoHFW), including testing strategy advisories, surveillance guidelines, and clinical management protocols, as well as World Health Organization (WHO) surveillance and case definition guidance and recent peer-reviewed literature from 2015–2025. Documents were selected if they described COVID-19 case definitions, testing strategies, surveillance approaches, or treatment protocols relevant to India, with emphasis on updates issued between 2020 and 2023. **Results:** Updated Indian guidelines progressively shifted from broad community testing and hospitalization to purposive testing focused on high-risk groups and structured home/institutional care pathways, while surveillance moved toward integrated, variant-sensitive systems aligned with WHO case definitions. This approach has evolved from empiric repurposed drugs to evidence-based oxygen therapy, steroids for hypoxic patients, thromboprophylaxis, and rational use of antivirals and immunomodulators.

Conclusion: Updated methodological guidelines have strengthened India's capacity for early detection, risk-stratified testing, and standardized management of COVID-19 while offering

rich opportunities to teach core competencies in epidemiology, clinical reasoning, and evidence-based practice to undergraduate students.

INTRODUCTION

COVID-19, virus strain SARS-CoV-2, caused a global pandemic that emerged in early 2020.

- In India, the first cases were reported on 30 January 2020.

The pandemic evolved in a number of waves, with variable intensity, community-wide transmission, and the emergence of new variants. Coronavirus disease 2019 (COVID-19) has presented unparalleled diagnostic and therapeutic challenges worldwide, with continuous updating of testing strategies and clinical care protocols.

India has reported tens of millions of confirmed cases and undergone multiple variant-driven waves, making robust methodological guidance central to public health control and clinical outcomes.

- Existing knowledge: There have been a raft of documents on testing strategies,

Home-isolation protocols, and clinical management guidelines; however, no comprehensive review has been undertaken to track how these evolving guidelines influenced case detection rates and management practices in India. There is also a paucity of published data on their effectiveness, especially in the recent phases. Early in the pandemic, ICMR and MoHFW released interim advisories on testing and clinical management, which were subsequently updated to accommodate wider testing, new therapeutics, home-based care and resource constraints in a large, diverse health system.

- Gaps: There is a need, for undergraduate medical education and for clinicians,

For a comprehensive summary and critical appraisal of how the guidelines changed over time, what impact that might have had, and what challenges remain. Despite abundant documents, there is relatively limited synthesis for undergraduate learners focusing on how methodological changes in guidelines directly influenced who was tested, which cases were identified, and how patient management evolved in India.

Understanding these dynamics is crucial for future physicians who must interpret evolving evidence, apply national protocols, and participate in outbreak response. Objective: To review the impact of updated COVID-19 methodological guidelines on case detection and clinical management in India and to outline key educational implications for undergraduate medical training

- Rationale:

A narrative review synthesizing guideline evolution helps students understand real-world

public health response, appreciate dynamic healthcare policy adaptations, and critically evaluate limitations — important preparation for future physicians. How national and international guidance evolved-and how that influenced clinical decision-making-is important for students who will be managing respiratory outbreaks and future pandemics.

- Aim:

Review the evolution of methodological guidelines in COVID-19 management in India from 2020 to 2025 and their impacts on case detection and management practices.To review updated COVID-19 methodological guidelines affecting case detection and clinical management in India and to derive key implications for undergraduate medical training.

Methods

Study design: This article is a narrative review focusing on guideline evolution and its practical implications rather than on a formal meta-analysis.

Data sources: The primary sources included official Indian documents from ICMR and MoHFW on testing strategy advisories, operational guidelines for surveillance, and national clinical management protocols for adult COVID-19 patients, updated as of January 2023.

The international sources included WHO documents regarding public health surveillance, COVID-19 case definitions, and living clinical management guidelines.

Additional peer-reviewed articles on case definitions, diagnostic testing approaches, and outcomes were identified through PubMed and open repositories.

Inclusion and exclusion criteria included documents that: 1) focused on SARSCoV-2; 2) focused on case definitions, testing strategy, surveillance or clinical management; 3) were applicable to the Indian setting or global guidance adopted in India and 4) were published or updated from January 2020 onwards with selective inclusion of key living guidelines updated to 2023.

Materials which focused on non-human surveillance alone, on non-COVID respiratory infections, or on purely economic analyses devoid of clinical content were excluded. Time frame: The search and selection included documents issued between January 2020 and early 2023 related to Indian guidelines and the years 2020-2023 for WHO guidance on surveillance and management, enabling the coverage of main waves and the subsequent endemic phase.

Data extraction and synthesis Data were extracted for each included guideline on the following: (a) case definitions, (b) indications and modalities of testing, (c) approach to surveillance, and (d) recommendations on clinical management for mild, moderate, and severe

disease.

Information was summarized into thematic domains: evolution of case definitions, testing strategies, clinical pathways, and implications for teaching. Descriptive statistics were generated using hypothetical but realistic examples consistent with the types of data reported in Indian and WHO documents to construct tables and graphs suitable for undergraduate learning.

Ethical consideration: Since this review is based on publicly available policy documents and published literature devoid of patient-level data, formal ethics approval was not required.

RESULTS

Below is a chronological summary of major guideline updates and their features

1. **Early Phase, 2020** - containment & symptomatic testing

Initial testing strategy focused on people with recent international travel, symptomatic contacts, health care workers, symptomatic ILI/SARI, symptomatic hospitalized patients, and migrants/returnees.

Case definition for "suspect case" was stringent: Acute respiratory illness (fever + respiratory symptoms) plus travel history or contact with confirmed case.

Testing: the standard was to be real-time RT-PCR for suspected cases; rapid tests were limited.

Management: COVID cases, especially symptomatic ones, were hospitalized or sent to dedicated COVID-facilities. Home isolation was allowed only in very mild/pre-symptomatic cases under strict conditions.

2. **Mid-Pandemic (2021–2022)** — Expanding Home Isolation & Update on Management Protocols

MoHFW issued "Revised guidelines for Home Isolation of mild / asymptomatic COVID-19 cases" on 29 April 2021.

As per these guidelines, asymptomatic or mild cases-meaning upper respiratory symptoms and/or fever, no breathlessness, oxygen saturation >94% on room air-were eligible for home isolation.

Exclusion criteria included patients with comorbidities, immunocompromised status, or lower oxygen saturation, all of whom required hospital care.

The clinical management protocols were periodically updated: discharge policy, pediatric and adult management guidelines, and post-COVID care.

It relieved the burden on hospitals and conserved resources, making care more scalable, which is important given the large population and limited capacities of hospitals in many regions.
In 2022, with improved vaccination coverage and reduced severity in most cases, home isolation became standard for mild disease while hospital resources were reserved for moderate to severe cases.

3. **Recent updates: 2023–2025** — Vigilance with variants, renewed testing & preparedness
   In March 2023, MoHFW updated the "Clinical Guidance for Management of Adult COVID-19 Patients.

In 2025, with the detection of new subvariants, for example, NB.1.8.1 and LF.7, fresh advisories were issued by the authorities. It advices hospitals to enhance preparedness regarding bed availability, oxygen, and ventilators, and scale up surveillance through ILI/SARI reporting, conduct genome sequencing of positive samples, and test a proportion of ILI/SARI cases.

New guidance emphasized: cautious use of antibiotics only with suspicion of bacterial infection, systemic corticosteroids not indicated in mild disease, symptomatic management-hydration, antipyretics, and antitussives-monitoring of temperature and oxygen saturation at home, and contacting the physician if any red-flag symptoms manifest.

Some states-for example, southern India-reinforced COVID testing for all presenting with ILI/ARI/SARI, even if Ag-negative; negative rapid tests must be followed by RT-PCR.
These updates reflect a strategic shift, according to which there should be more surveillance, flexible home isolation, capacity to respond to variant-driven resurgences, and rationalized clinical management to avoid overuse of medical interventions.

Period/Date	**Key guidelines Document/ Event**	**Changes in case detection/ Testing/ Management**
Early 2020	ICMR testing strategy, initial case definitions	Asymptomatic/mild cases eligible for home isolation (SpO_2 > 94%, no breathlessness)
29 apr 2021	Revised Home Isolation guidelines	Asymptomatic/mild cases eligible for home isolation (SpO_2 > 94%, no breathlessness)

2021-2022	Periodic updates: discharge policy, pediatric & adult management	Expanded home care, updated discharge and care protocols, reduced hospital burden.
2023-2025	Strict testing criteria (travel/contact history, ILI/SARI), RT-PCR only, mostly hospital-based care	Emphasis on ILI/SARI surveillance, genome sequencing, hospital preparedness, rational use of drugs (no steroids/antibiotics in mild disease), symptomatic management, early detection & isolation.

Summary of Main Findings:

- Over 2020–2025, COVID-19 guidelines in India evolved from restrictive testing and hospital-centric care to a more flexible, resource-sensitive approach that emphasizes home isolation for mild cases, rationalized treatment, surveillance, and preparedness for variant-driven surges.
- These methodological guideline updates potentially improved scalability of response, reduced hospital burden, and allowed better allocation of resources (oxygen, ICU beds) for moderate/severe cases.
- The 2025 wave (driven by subvariants) triggered renewed emphasis on surveillance (ILI/SARI), genome sequencing, and judicious clinical management — demonstrating the adaptive nature of guideline policy in India's public health response.

Evolution of case definitions and surveillanceThe WHO surveillance guidance updated in 2022 defined standardized suspected, probable, and confirmed case categories and emphasized integration of clinical, epidemiological, and laboratory criteria, which India used to refine national surveillance strategies.

The revised surveillance strategy adopted by MoHFW prioritized the early detection and isolation of symptomatic people, high-risk groups, and the detection of new variants through genomic surveillance, backed by a nationwide laboratory network described by ICMR.

Table 1: Hypothetical distribution of COVID-19 cases by WHO-aligned surveillance category in an Indian tertiary hospital (n=1,000)[Data pattern constructed for teaching

illustration consistent with shifts expected after clearer definitions and improved testing access based on WHO and MoHFW surveillance guidance.

CATEGORY	EARLY PHASE (2020) n (%)	LATER PHASE (2022) n (%)
Suspected	500 (50)	300 (30)
Probable	200 (20)	150 (15)
Confirmed	300 (30)	550 (55)



Changes in testing strategy and modalitiesICMR's calibrated testing strategy moved from widespread RT-PCR based testing in early 2020 to a purposive testing approach focusing on high-risk populations, symptomatic individuals, and sentinel surveillance, while incorporating multiple modalities such as RT-PCR, TrueNat, CBNAAT, RT-LAMP, and rapid antigen tests. The advisory on purposive testing 2022 had specified groups where testing was not routinely needed-for example, asymptomatic low-risk individuals-to avoid over-testing and to preserve capacity for high-yield indications.

Table 2 demonstrates a hypothetical distribution of diagnostic modalities during different phases, reflecting trends in line with national guidance for increased deployments of Rapid Antigen Tests for triage and RT-PCR for confirmation and genomic sampling.

Table 2: Distribution of COVID-19 diagnostic modalities in India: Hypothetical, by phase of the pandemic (n = 10,000 tests per phase)[The pattern reflects an increasing

diversification of testing, to be consistent with ICMR advisories on purposive testing and multiple platforms.

MODALITY	EARLY PHASE	SECOND WAVE	ENDEMIC PHASE
RT-PCR	7000	5000	3500
Rapid antigen test	2000	3500	4500
Truenat/CBNAAT	800	1000	1200
Other	200	500	800

A teaching conceptual pie chart of the proportional use of these modalities in the endemic phase (2023) would probably show rapid antigen tests as the largest, followed by RT-PCR, then TrueNat/CBNAAT, and other assays.

Evolution of Clinical Management Protocols The MoHFW's clinical management protocols for COVID-19 steadily outlined clear pathways for mild, moderate and severe disease, besides the criteria for home isolation, ward admission, and ICU care.

Subsequent versions were focused on evidence-based employment of low-dose steroids in hypoxic patients, anticoagulation where indicated, cautious use of antivirals and monoclonal antibodies, and avoidance of unproven therapies.

Table 3: Simplified, guideline-aligned categorization of adult patients by severity and typical setting of care in an Indian hospital following updated 2023 clinical guidance.

Table 3. Hypothetical distribution of adult COVID-19 patients by severity and care setting post-updated 2023 guidance (n = 500) Distribution reflects increased use of home and ward-based care with ICU reserved for severe/critical cases consistent with MoHFW adult management guidance

Conceptual graphs and pie charts for teachingA line graph can be constructed to show a hypothetical decline in hospital admissions per 1,000 detected cases over time as home-based care and triage improve under updated protocols, with separate lines for mild, moderate, and severe disease aligned to MoHFW guidance.

According to Table 3, a pie chart showing the proportion of cases detected and allocated to home isolation, ward care, and ICU care in 2023 can illustrate the improved triage impact on resource utilization.

SEVERITY LEVEL	HOME ISOLATION	WARD n(%)	ICU n(%)
MILD	250	20. (4)	0 (0)
MODERATE	20	140 (28)	10 (2)
SEVERE	0	20 (4)	40 (8)

Discussion Updated COVID-19 methodological guidelines in India have progressively shifted

the focus away from broad, resource-intensive approaches and toward targeted evidence-based strategies for building detection and management capacity; thereby improving the yield of testing and the appropriateness of clinical care.

Taken together, the shift from widespread RT-PCR testing to purposed multimodal testing, informed by WHO-harmonized case definitions and surveillance goals, serves to better identify clinically informative cases and more accurately monitor variants, while limiting superfluous testing of low-risk populations.

These changes run parallel to WHO's 2022 surveillance guidance that emphasized clear case definitions, the integration of genomic surveillance, and flexible reporting frameworks. India's operational guidelines for revised surveillance strategies reflect this alignment.
This intersection between global guidance and national adaptation is, for undergraduates, an illustration of how concepts in epidemiology like sensitivity/specificity trade-offs, targeted screening, and risk-stratified surveillance find practical application.

In clinical management, the evolution of MoHFW from early less certain protocols to the later documents emphasizing oxygen therapy, prone positioning, rational steroid use, and thromboprophylaxis reflects the evolution of the WHO living clinical management guideline that incorporated emerging trial evidence.
For the student, this illustrates a very important principle: that high-quality randomized trials can change practice quickly and treatment recommendations should be critically appraised rather than followed uncritically.
These hypothetical tables and graphs depict how new guidelines might change the apparent epidemiology of disease: a higher proportion confirmed among those tested, a shift in diagnostic modality mix, and a greater proportion of patients safely managed at home due to clearer severity criteria and follow-up protocols.

Pie chart: Proportion of guideline versions (early, mid, later) that include each major diagnostic modality (RT-PCR only vs RT-PCR + rapid antigen vs multiple modalities). Use hypothetical percentages (for example, early 100% RT-PCR only; mid 60% RT-PCR + RAT; late 70% multiple modalities) and label clearly for illustration in a student review. Base the categorization on narrative descriptions from ICMR documents.

Line graph: Schematic trend of daily tests and detected cases over major guideline phases

using approximate values or stylized curves (not exact surveillance data) to demonstrate how expanded eligibility and decentralization could increase observed caseloads





Such visualizations are valuable for teaching data interpretation, including understanding denominators, selection bias, and how triage decisions influence ICU occupancy and mortality. From an educational perspective, these evolving guidelines can be integrated into undergraduate curricula to teach:

1. formulation and application of case definitions;
2. constructing diagnostic algorithms using multiple tests;
3. triage and severity scoring; and

4. Principles of evidence-based guideline appraisal.

It uses real national documents in problem-based learning to help students link classroom epidemiology to bedside decisions about public-health policy, strengthening preparedness for future outbreaks.

Strengths of this review include the focus on official Indian and WHO documents and the alignment of synthesized findings with practical learning goals for undergraduates.

Limitations include a reliance on policy documents rather than primary clinical data sets and the use of hypothetical numerical examples for tables and graphs, which means quantitative estimates are illustrative rather than measured.

Conclusion Updated COVID-19 methodological guidelines in India, covering surveillance and testing strategy and clinical management, have enhanced the targeting of diagnostic resources and standardized care pathways, especially for adults with mild, moderate, and severe disease.

These guidelines offer a real-world framework to provide undergraduate medical training in epidemiologic reasoning, rational test use, and evidence-based therapeutics; thus, preparedness for future physicians in the management of endemic COVID-19 is ensured, as well as for future pandemics.

DISCUSSION

Interpretation: Guideline evolution indicates a pragmatic balancing act. With the pandemic stretching health infrastructure, India moved from a "test everybody"/hospitalize approach to risk-based home isolation and selective hospitalization, appropriate for a large population with limited resources. The updates for 2025 indicate preparedness for new threats that will be met with enhanced surveillance and targeted interventions.

Comparison with global / WHO guidance: The shift is in line with the global trend of treating mild cases at home when possible, focusing on oxygen/ICU resources for severe disease, and ramping up genomic surveillance when variants emerge. Flexibility to revise guidelines shows responsiveness to changing epidemiology.

Clinical relevance to India and other LMICs: For a clinician and public health professional, this evolution is important to understand that guidelines are never static; management needs to be updated based on current context - variant, resource availability, and burden. For medical students, a review of these changes helps appreciate how real-world public health policy and resource-limited care strategies work.

Strengths of the review include: it collates national-level documents over time; bridges guideline history with recent developments; useful for educational purposes.

Limitations/challenges: Lack of published outcome data, variable implementation across states, rapidly changing variant landscape, difficult to assess real-world impact.

Recommendations for practice: Continued ILI/SARI surveillance, genomic sequencing; appropriate public health infrastructure; frank public communication-home isolation, red-flag symptoms, when to seek hospital care; periodically review these guidelines.
Future Research Directions: Investigations of the following may be considered: a) adherence to guidelines across different states; b) impact on rates of hospitalizations, mortality, hospital burden; c) effectiveness of home isolation protocols; d) real-life outcomes following changes in guidelines; e) qualitative studies on experiences of patients and clinicians.

CONCLUSION: Dynamic updates of the COVID-19 methodological guidelines in India have played a key role in the adaptation of case detection and management strategies to changing epidemiology, resource constraints, and the challenge of emerging variants. For medical students and clinicians, comprehension of this evolution offers an invaluable lesson in public health responsiveness, clinical prudence, and pragmatic healthcare delivery in resource-limited settings.

REFERENCES

1. https://covid19.india.gov.in/document/revised-guidelines-for-home-isolation-of-mild-asymptomatic-covid-19-cases
2. https://covid19dashboard.mohfw.gov.in
3. agumch.org
4. health.uk.gov.in
5. https://www.icmr.gov.in
6. https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022
7. https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_De finition-2022.1
8. https://dhs.kerala.gov.in/wp-content/uploads/2022/01/Advisory-Purposive-Testing-Strategy-Jan-2022

9. https://covid19dashboard.mohfw.gov.in/pdf/OperationalGuidelinesforRevisedSurveillanceStrategyincontextofCOVID-1
10. https://covid19dashboard.mohfw.gov.in
11. https://covid19dashboard.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021
12. https://www.ncbi.nlm.nih.gov/books/NBK582435/pdf/Bookshelf_NBK582435
13. Indian Council of Medical Research. Strengthening crisis investigations and calibrated testing strategy.
14. Government of India, Ministry of Health & Family Welfare. Advisory on Purposive Testing Strategy for COVID-19 in India, Version VII, 2022.
15. Ministry of Health & Family Welfare, Govt. of India. Operational Guidelines for Revised Surveillance Strategy in context of COVID-19.
16. Ministry of Health & Family Welfare, Govt. of India. Clinical Management Protocol for COVID-19 (Adults), 24 May 2021.
17. Ministry of Health & Family Welfare, Government of India. Clinical Management Protocol: COVID-19, 2020.
18. Ministry of Health & Family Welfare, Govt. of India. Clinical guidance for management of adult COVID-19 patient, revised 05 January 2023.
19. World Health Organization. Public health surveillance for COVID-19: interim guidance,
20. 2022.
21. World Health Organization. WHO COVID-19 case definition, 2022 update.
22. World Health Organization. Clinical management of COVID-19: living guideline, 2023 update.
23. WHO COVID-19 dashboard and situation data NITI Aayog/ICMR. Guidelines for sharing of biospecimen and data for research related to COVID-19. Government of India.
24. COVID-19 India resources and testing notifications. Regional/state COVID-19 guideline repositories, such as state health department portals.